Research programme: pharmacological chaperones - Cantabio Pharmaceuticals

Drug Profile

Research programme: pharmacological chaperones - Cantabio Pharmaceuticals

Alternative Names: CB 101; CB 102

Latest Information Update: 25 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Gardedam Therapeutics; Purdue University
  • Developer Cantabio Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Reactive oxygen species modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Parkinson's disease

Most Recent Events

  • 08 Apr 2017 Cantabio intends to files an IND application for CB 101 in Parkinson's disease with the US FDA in 2019
  • 11 Jul 2016 Cantabio Pharmaceuticals signs a cooperation agreement with Purdue Research Foundation for studies on pharmacological chaperones for Parkinson's disease and other neurodegenerative disorders
  • 16 Jun 2016 Cantabio and University of Antioquia agree to co-develop DJ-1 protein-targeting small molecule in USA for Parkinson's disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top